PMID- 35534674
OWN - NLM
STAT- MEDLINE
DCOM- 20230228
LR  - 20230228
IS  - 1435-232X (Electronic)
IS  - 1434-5161 (Linking)
VI  - 68
IP  - 3
DP  - 2023 Mar
TI  - Avoidance of cutaneous adverse drug reactions induced by antiepileptic drugs 
      based on pharmacogenomics.
PG  - 227-230
LID - 10.1038/s10038-022-01040-1 [doi]
AB  - Pharmacogenomics (PGx) is a research area aimed at identifying genetic factors 
      that are associated with drug responses, including drug efficacy, adverse drug 
      reactions, and the appropriate drug dosage on a case-to-case basis. To promote 
      the clinical implementation of PGx testing, which is currently of limited use in 
      clinical practice, recent research has focused on providing reliable evidence for 
      its clinical utility. In neurology, psychiatry, and neurosurgery, several human 
      leukocyte antigen (HLA) alleles have been reportedly associated with cutaneous 
      adverse drug reactions (cADRs) induced by antiepileptic drugs, which 
      significantly carry the risk of developing cADRs. Prior to using antiepileptic 
      drugs such as carbamazepine and lamotrigine, which are prone to cause severe 
      cADRs, preemptive HLA genetic testing and therapeutic interventions such as drug 
      selection and dosage adjustment based on the results of the tests can reduce the 
      incidence of cADRs in the population before the initiation of treatment.
CI  - (c) 2022. The Author(s), under exclusive licence to The Japan Society of Human 
      Genetics.
FAU - Mushiroda, Taisei
AU  - Mushiroda T
AD  - Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, 
      Yokohama, 230-0045, Japan. mushiroda@riken.jp.
LA  - eng
GR  - H26-nanchi(nan)-ippan-081/Ministry of Health, Labour and Welfare (Ministry of 
      Health, Labour and Welfare, Japan)/
PT  - Journal Article
PT  - Review
DEP - 20220509
PL  - England
TA  - J Hum Genet
JT  - Journal of human genetics
JID - 9808008
RN  - 0 (Anticonvulsants)
RN  - U3H27498KS (Lamotrigine)
RN  - 33CM23913M (Carbamazepine)
SB  - IM
MH  - Humans
MH  - *Anticonvulsants/adverse effects
MH  - Pharmacogenetics
MH  - Lamotrigine
MH  - Carbamazepine/adverse effects
MH  - *Drug-Related Side Effects and Adverse Reactions
EDAT- 2022/05/10 06:00
MHDA- 2023/03/03 06:00
CRDT- 2022/05/09 23:26
PHST- 2022/03/05 00:00 [received]
PHST- 2022/04/20 00:00 [accepted]
PHST- 2022/04/07 00:00 [revised]
PHST- 2022/05/10 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PHST- 2022/05/09 23:26 [entrez]
AID - 10.1038/s10038-022-01040-1 [pii]
AID - 10.1038/s10038-022-01040-1 [doi]
PST - ppublish
SO  - J Hum Genet. 2023 Mar;68(3):227-230. doi: 10.1038/s10038-022-01040-1. Epub 2022 
      May 9.